Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1002 - A nomogram for predicting overall survival (OS) in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens


08 Oct 2016


Poster Display


Wataru Ichikawa


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


W. Ichikawa1, K. Uehara2, K. Minamimura3, C. Tanaka4, Y. Takii5, H. Miyauchi6, S. Sadahiro7, K. Shinozaki8, K. Fukumoto9, T. Otsuji10, T. Kambara11, S. Morita12, Y. Ando13, M. Arai14, M. Sugihara15, T. Sugiyama16, Y. Ohashi17, Y. Sakata18

Author affiliations

  • 1 Division Of Medical Oncology, Showa University School of Medicine, 142-8666 - Tokyo/JP
  • 2 Department Of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya/JP
  • 3 Department Of Surgery, Mitsui Memorial Hospital, Tokyo/JP
  • 4 Department Of Surgery, Gifu Prefectural General Medical Center, Gifu/JP
  • 5 Department Of Surgery, Niigata Cancer Center Hospital, Niigata/JP
  • 6 Department Of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba/JP
  • 7 Department Of Surgery, Tokai University, Isehara/JP
  • 8 Division Of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima/JP
  • 9 Department Of Surgery, Nishijin Hospital, Kyoto/JP
  • 10 Department Of Gastroenterology, Dongo Hospital, Yamatotakada/JP
  • 11 Department Of Surgery, Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital, Fukuyama/JP
  • 12 Department Of Biomedical Statistics And Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto/JP
  • 13 Department Of Clinical Oncology And Chemotherapy, Nagoya University Hospital, Nagoya/JP
  • 14 Pharmacovigilance Department, Daiichi Sankyo, Tokyo/JP
  • 15 Clinical Data & Biostatistics Department, Daiichi Sankyo, Tokyo/JP
  • 16 Department Of Obsterics And Gynecology, Iwate Medical University School of Medicine, Morioka/JP
  • 17 Department Of Integrated Science And Engineering For Sustainable Society, Chuo University Faculty of Science and Engineering, Tokyo/JP
  • 18 Ceo, Misawa City Hospital, Misawa/JP


Abstract 1002


One of the standard treatments for aCRC is IRI-based regimens, which are commonly used as second line treatment in Japan. We conducted a prospective observational study to examine the correlation between UGT1A1 genotypes and the clinical outcome of IRI-based regimens in Japanese pts with aCRC (NCT 01039506). We presented previously the results of OS, the secondary endpoint (ASCO 2015, Abst No. 3525). Furthermore, We are going to present update results of OS (ASCO 2016, Abst No. 3571). We developed a nomogram for predicting survival of pts treated with second-line IRI-based regimens after first-line oxialiplatin-based treatment.


From Oct 2009 to Mar 2012, 1,376 pts with histologically confirmed aCRC treated with IRI-based regimens were enrolled into the study. Among all enrolled pts, 747 pts were treated with the second-line IRI-based regimens after first-line oxialiplatin-based treatment. A nomogram for predicting OS was developed using multivariable Cox proportional hazards model. The discriminative ability and predictive accuracy of the nomogram were determined by concordance index (c-index) and calibration plot. The nomogram was internally validated using bootstrap resampling.


The median OS was 18.5 months (95% CI, 16.8 – 20.7). The multivariable Cox proportional hazards model included age, performance status, resection of primary tumor, location of primary tumor (right vs left), tumor burden based on longitudinal diameters of target lesions according to the RECIST criteria, diabetes and white blood cell count as predictors of OS. The resulting nomogram demonstrated good discrimination and calibration in predicting OS, with a bootstrap-corrected c-index of 0.68. The nomogram showed good separation between risk groups stratified by tertile of the total score, with median OS of 10.1, 18.6, and 29.4 months for low, middle, and high risk groups, respectively.


This proposed nomogram is well calibrated and internally validated. External validation is essential before implementing this nomogram in clinical practice.

Clinical trial identification

NCT 01039506, first released on 23/Dec/2009. The trial protocol number is TOP009-061.

Legal entity responsible for the study

Daiichi Sankyo


Daiichi Sankyo


W. Ichikawa, S. Morita, Y. Ando, T. Sugiyama, Y. Ohashi: Advisory Board members of this study. Honoraria from Daiichi Sankyo. Y. Takii: Honoraria from Daiichi Sankyo. M. Arai: Employee of Daiichi sankyo. M. Sugihara: Employee of Daiichi Sankyo. Y. Sakata: Advisory Board members of this study. Honoraria from Daiichi Sankyo, Taiho Pharmaceutical, Yakult Honsya. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings